Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel Add-on in Partial Onset Seizures
NCT02726074Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2016
- Primary completion
- Apr 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perampanel in epilepsy, sponsored by Eisai Co., Ltd. Primary endpoint: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization at 36 weeks. Started May 2016; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02726074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726074.